As shown in Figure 5A, TUBO- bearing mice that received Class I (p66) HER2 peptide pulsed DC1 concurrently with intraperitoneal injection of anti-PD-1 or anti-PD-L1 monoclonal antibodies had no significant delay in the tumor growth compared to mice treated with class I (p66) HER2-DC1 alone. Here, CD274 is linked to neoplasm.